Recent News

JOT receives Orphan Drug Designation for its trans-resveratrol product  JOTROL™​ for treatment of Friedreich's Ataxia!

JOT SAB Meeting at Harvard Faculty Club in Boston, Massachusetts. "Monumental Day" as David Sinclair described it! Review of existing and upcoming clinical programs as well as targeting of new indications.